Progression on BTK Inhibitors: Treatment Options and Considerations

Video content above is prompted by the following:

• Briefly comment on the role of combination venetoclax-ibrutinib in this setting and available supporting data (high level).
  • CLARITY – Hillmen P. et al. J Clin Oncol. 2019;37(30):2722-2729
  • VISION – Kater AP, et al. Lancet Oncol. 2022;23(6):818-828
• What is the potential role for venetoclax in combination with 2nd generation BTKis in this setting? (Ahn IE, et al. ASH 2024. Abs 1874)
• Briefly review recent ESMO guideline updates for managing patients with R/R CLL who experience disease progression on a BTKi. (ESMO CLL Guideline Update 2024)
• How does your treatment approach differ for patients who progress on first-line BTK inhibitor therapy versus those who are intolerant to it?
• When would you opt for an alternative BTKi vs changing to a venetoclax-based regimen?